Polar Capital’s Acceleron Pharma XLRN Stock Holding History

Polar Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$17.8M	Buy	157,762 +59,684	+61%	+$5.94M	0.13%	142
2020 Q2	$9.34M	Buy	98,078 +23,078	+31%	+$2.22M	0.08%	178
2020 Q1	$6.74M	Buy	+75,000	New	+$5.83M	0.07%	189
2018 Q3	–	Sell	-324,185	Closed	-$15.7K	–	291
2018 Q2	$15.7K	Sell	324,185 -748,713	-70%	-$27.3M	0.09%	170
2018 Q1	$42M	Buy	1,072,898 +42,898	+4%	+$1.82M	0.42%	79
2017 Q4	$43.7M	Sell	1,030,000 -35,000	-3%	-$1.31M	0.45%	65
2017 Q3	$39.7M	Sell	1,065,000 -10,000	-0.9%	-$347K	0.45%	71
2017 Q2	$32.7M	Buy	1,075,000 +325,000	+43%	+$9.42M	0.44%	81
2017 Q1	$19.9M	Buy	750,000 +212,412	+40%	+$5.6M	0.3%	113
2016 Q4	$13.7M	Buy	+537,588	New	+$17M	0.22%	134
2015 Q2	–	Sell	-14,049	Closed	-$535K	–	309
2015 Q1	$535K	Buy	+14,049	New	+$559K	0.01%	268

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Polar Capital's XLRN Position: Q3 2020 in Review

Polar Capital increased its Acceleron Pharma (XLRN) stake by 61% in Q3 2020, buying an estimated $5.94M and bringing the position to 157,762 shares worth $17.8M. The position accounts for 0.13% of the portfolio, ranked #142.

Polar Capital first reported a position in XLRN in Q1 2015 and has held it in 11 quarters since. The position peaked at $43.7M in Q4 2017. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

Polar Capital held 157,762 shares of Acceleron Pharma worth $17.8M as of Q3 2020.
Polar Capital bought 59,684 Acceleron Pharma shares in Q3 2020, an estimated $5.94M.
Acceleron Pharma made up 0.13% of Polar Capital's portfolio in Q3 2020, its #142 holding.
Polar Capital first reported a position in Acceleron Pharma in Q1 2015 and has held it in 11 quarters since.
Polar Capital's Acceleron Pharma position peaked at $43.7M in Q4 2017.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.